RGNX
$36.14
Regenxbio
$1.11
3.17%
RGNX
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.87)
Revenue:  $31.49 Mil
Wednesday
Nov 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RGNX reports earnings?
Beat
Meet
Miss

Where is RGNX's stock price going from here?
Up
Flat
Down
Stock chart of RGNX
Analysts
Summary of analysts' recommendations for RGNX
Score
Grade
Pivots
Resistance
$38.65
$37.44
$36.79

$35.59

Support
$34.94
$33.73
$33.08
Tweet
Growth
Description
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.